
Axiom Biosciences Targets US$200M Hong Kong IPO in 2027, US Listing in 2029
Axiom Biosciences, a US-based biotech firm developing AI-powered therapies for newborn brain injuries, is targeting a US$200 million initial public offering (IPO) in Hong Kong by 2027, with a secondary listing in the US planned for 2029. CEO Remo Moomiaie-Qajar highlighted Hong Kong's mature market for healthcare listings.













